JP2014530215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530215A5 JP2014530215A5 JP2014533618A JP2014533618A JP2014530215A5 JP 2014530215 A5 JP2014530215 A5 JP 2014530215A5 JP 2014533618 A JP2014533618 A JP 2014533618A JP 2014533618 A JP2014533618 A JP 2014533618A JP 2014530215 A5 JP2014530215 A5 JP 2014530215A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- seq
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 47
- 102000036639 antigens Human genes 0.000 claims 47
- 108091007433 antigens Proteins 0.000 claims 47
- 239000012634 fragment Substances 0.000 claims 47
- 239000003814 drug Substances 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 230000004614 tumor growth Effects 0.000 claims 4
- 102000048238 Neuregulin-1 Human genes 0.000 claims 3
- 108090000556 Neuregulin-1 Proteins 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010029098 Neoplasm skin Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000023958 prostate neoplasm Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541312P | 2011-09-30 | 2011-09-30 | |
| US61/541,312 | 2011-09-30 | ||
| US201161557460P | 2011-11-09 | 2011-11-09 | |
| US61/557,460 | 2011-11-09 | ||
| US201261614565P | 2012-03-23 | 2012-03-23 | |
| US61/614,565 | 2012-03-23 | ||
| PCT/US2012/056446 WO2013048883A2 (en) | 2011-09-30 | 2012-09-21 | Anti-erbb3 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017248591A Division JP6563472B2 (ja) | 2011-09-30 | 2017-12-26 | 抗ＥｒｂＢ３抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530215A JP2014530215A (ja) | 2014-11-17 |
| JP2014530215A5 true JP2014530215A5 (https=) | 2015-11-05 |
| JP6271432B2 JP6271432B2 (ja) | 2018-01-31 |
Family
ID=46970445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533618A Active JP6271432B2 (ja) | 2011-09-30 | 2012-09-21 | 抗ＥｒｂＢ３抗体およびその使用 |
| JP2017248591A Active JP6563472B2 (ja) | 2011-09-30 | 2017-12-26 | 抗ＥｒｂＢ３抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017248591A Active JP6563472B2 (ja) | 2011-09-30 | 2017-12-26 | 抗ＥｒｂＢ３抗体およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US8791244B2 (https=) |
| EP (1) | EP2760893B1 (https=) |
| JP (2) | JP6271432B2 (https=) |
| KR (1) | KR20140069331A (https=) |
| CN (1) | CN103917562B (https=) |
| AR (1) | AR088171A1 (https=) |
| AU (2) | AU2012316402B2 (https=) |
| BR (1) | BR112014007382A2 (https=) |
| CA (1) | CA2849508C (https=) |
| CL (1) | CL2014000758A1 (https=) |
| CO (1) | CO6940383A2 (https=) |
| EA (2) | EA028879B1 (https=) |
| ES (1) | ES2694153T3 (https=) |
| HK (1) | HK1200468A1 (https=) |
| IL (2) | IL231318B (https=) |
| IN (1) | IN2014CN03042A (https=) |
| MX (1) | MX357391B (https=) |
| PH (1) | PH12014500483A1 (https=) |
| SG (1) | SG11201400150TA (https=) |
| TW (2) | TW201329103A (https=) |
| WO (1) | WO2013048883A2 (https=) |
| ZA (1) | ZA201401424B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS54795B1 (sr) | 2009-12-22 | 2016-10-31 | Roche Glycart Ag | Anti-her3 antitela i njihova korišćenja |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| PH12014500483A1 (en) | 2011-09-30 | 2014-04-14 | Regeneron Pharma | Anti-erbb3 antibodies and uses thereof |
| DK2797957T3 (da) | 2011-11-23 | 2019-09-23 | Medimmune Llc | Bindingsmolekyler specifikke for her3 og anvendelser deraf |
| AR093778A1 (es) | 2012-11-08 | 2015-06-24 | Hoffmann La Roche | PROTEINAS LIGANTES DE ANTIGENO ANTI-HER3/HER4 DE UNION A LA HORQUILLA b DE HER3 Y A LA HORQUILLA b DE HER4 |
| KR20150131312A (ko) * | 2013-03-15 | 2015-11-24 | 미르나 테라퓨틱스 인코포레이티드 | 마이크로rna 및 egfr-tki 억제제를 이용한 조합 암 치료 |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| US20160232293A1 (en) * | 2013-10-17 | 2016-08-11 | Sanford-Burnham Medical Research Institute | Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers |
| KR102127408B1 (ko) | 2014-01-29 | 2020-06-29 | 삼성전자주식회사 | 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체 |
| JP6771385B2 (ja) | 2014-02-28 | 2020-10-21 | メルス ナムローゼ フェンノートシャップ | 二重特異性抗体および医薬組成物 |
| WO2015130173A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibody that binds erbb-2 and erbb-3 |
| WO2015157634A1 (en) * | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| WO2016011343A1 (en) * | 2014-07-17 | 2016-01-21 | The Trustees Of The University Of Pennsylvania | Her3 peptides and dendritic cell vaccines |
| CN105367657B (zh) * | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
| WO2016038609A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| EP3191523B1 (en) | 2014-09-08 | 2019-08-07 | Yeda Research and Development Co., Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| EP3334762A1 (en) * | 2015-08-14 | 2018-06-20 | Allergan, Inc. | Heavy chain only antibodies to pdgf |
| SMT202100230T1 (it) | 2015-10-23 | 2021-07-12 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Molecole di legame che inibiscono la crescita tumorale |
| KR101746152B1 (ko) | 2015-12-07 | 2017-06-13 | 주식회사 이수앱지스 | ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도 |
| MA43416A (fr) * | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| JP6729926B2 (ja) * | 2016-05-12 | 2020-07-29 | 国立大学法人神戸大学 | ＥｒｂＢ３活性化に伴うシグナルの伝達抑制物質及びそのスクリーニング方法 |
| CN117982673A (zh) | 2017-02-28 | 2024-05-07 | 第一三共株式会社 | 抗her3抗体-药物偶联物的应用 |
| IL269656B2 (en) | 2017-03-31 | 2024-06-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
| JP7296891B2 (ja) | 2017-05-17 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ |
| SG11202001050PA (en) | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
| CN107860925B (zh) * | 2017-11-03 | 2019-07-12 | 合肥瀚科迈博生物技术有限公司 | 用于检测血清中HuA21抗体的ELISA检测试剂盒 |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| WO2020059772A1 (ja) | 2018-09-20 | 2020-03-26 | 第一三共株式会社 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 |
| WO2020072937A1 (en) * | 2018-10-04 | 2020-04-09 | The Trustees Of The University Of Pennsylvania | Antibodies against basement membrane zone adhesion proteins bp180 and bp230 |
| EP4637821A1 (en) * | 2022-12-23 | 2025-10-29 | Actinium Pharmaceuticals, Inc. | Her3 radioimmunotherapy for the treatment of solid cancers |
| EP4721766A1 (en) | 2023-06-02 | 2026-04-08 | Daiichi Sankyo Company, Limited | Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| PT699237E (pt) | 1994-03-17 | 2003-07-31 | Merck Patent Gmbh | Fvs de cadeia anti-egfr e anticorpos anti-egfr |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| DE69736806T3 (de) | 1996-03-27 | 2015-10-08 | Genentech, Inc. | ErbB3 ANTIKÖRPER |
| DK1510579T3 (da) | 1998-02-04 | 2009-11-30 | Genentech Inc | Anvendelse af heregulin som en epitelcellevækstfaktor |
| US20010023241A1 (en) | 1998-02-04 | 2001-09-20 | Sliwkowski Mark X. | Use of heregulin as a growth factor |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| EP1228766A1 (en) | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
| CA2450285C (en) | 2001-06-13 | 2016-08-02 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| CA2450793A1 (en) * | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US7662374B2 (en) | 2001-08-03 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbB family members and methods of use thereof |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| WO2004008099A2 (en) | 2002-07-15 | 2004-01-22 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| WO2004079434A2 (en) | 2003-02-28 | 2004-09-16 | Northwestern University | Vapor deposited electro-optic films self-assembled through hydrogen bonding |
| UA101945C2 (uk) * | 2003-05-30 | 2013-05-27 | Дженентек, Инк. | Лікування злоякісного новоутворення за допомогою бевацизумабу |
| WO2005079434A2 (en) | 2004-02-17 | 2005-09-01 | The University Of North Carolina At Chapel Hill | Modulation of epidermal growth factor heterodimer activity |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| DK1951759T3 (da) * | 2005-11-12 | 2010-05-10 | Lilly Co Eli | Anti-EGFR-antistoffer |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| KR101598229B1 (ko) * | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| EP2138511A1 (en) | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| WO2010019952A2 (en) * | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
| WO2010083442A1 (en) * | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2010085845A1 (en) | 2009-01-28 | 2010-08-05 | The University Of Queensland | Cancer therapy and/or diagnosis |
| MY152068A (en) * | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
| EP2425009A4 (en) | 2009-04-29 | 2013-01-23 | Trellis Bioscience Llc | Improved antibodies immunoreactive with heregulin-coupled her3 |
| EA201200195A1 (ru) | 2009-08-21 | 2012-12-28 | Мерримаск Фармасьютикалс, Инк. | АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ |
| AU2010303443A1 (en) | 2009-10-09 | 2012-04-19 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-Her 3 antibodies |
| CA2780221A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| EP2896632B1 (en) | 2009-11-13 | 2017-10-25 | Daiichi Sankyo Europe GmbH | Material and methods for treating or preventing HER-3 associated diseases |
| RS54795B1 (sr) | 2009-12-22 | 2016-10-31 | Roche Glycart Ag | Anti-her3 antitela i njihova korišćenja |
| KR101853278B1 (ko) * | 2010-03-02 | 2018-05-02 | 애브비 인코포레이티드 | 치료학적 ｄｌｌ４ 결합 단백질 |
| KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| MX343227B (es) * | 2010-04-09 | 2016-10-28 | Aveo Pharmaceuticals Inc | Anticuerpos anti-erbb3. |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| AU2011290672B2 (en) | 2010-08-20 | 2015-07-09 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| PH12014500483A1 (en) * | 2011-09-30 | 2014-04-14 | Regeneron Pharma | Anti-erbb3 antibodies and uses thereof |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
-
2012
- 2012-09-21 PH PH1/2014/500483A patent/PH12014500483A1/en unknown
- 2012-09-21 EA EA201490717A patent/EA028879B1/ru not_active IP Right Cessation
- 2012-09-21 JP JP2014533618A patent/JP6271432B2/ja active Active
- 2012-09-21 SG SG11201400150TA patent/SG11201400150TA/en unknown
- 2012-09-21 CN CN201280045274.1A patent/CN103917562B/zh not_active Expired - Fee Related
- 2012-09-21 HK HK15100956.5A patent/HK1200468A1/xx unknown
- 2012-09-21 CA CA2849508A patent/CA2849508C/en active Active
- 2012-09-21 EP EP12768988.3A patent/EP2760893B1/en active Active
- 2012-09-21 MX MX2014003711A patent/MX357391B/es active IP Right Grant
- 2012-09-21 WO PCT/US2012/056446 patent/WO2013048883A2/en not_active Ceased
- 2012-09-21 EA EA201791393A patent/EA201791393A3/ru unknown
- 2012-09-21 KR KR1020147011692A patent/KR20140069331A/ko not_active Withdrawn
- 2012-09-21 BR BR112014007382A patent/BR112014007382A2/pt not_active IP Right Cessation
- 2012-09-21 IN IN3042CHN2014 patent/IN2014CN03042A/en unknown
- 2012-09-21 US US13/623,885 patent/US8791244B2/en active Active
- 2012-09-21 AU AU2012316402A patent/AU2012316402B2/en active Active
- 2012-09-21 ES ES12768988.3T patent/ES2694153T3/es active Active
- 2012-09-27 AR ARP120103601A patent/AR088171A1/es unknown
- 2012-09-28 TW TW101135734A patent/TW201329103A/zh unknown
- 2012-09-28 TW TW106116405A patent/TW201809012A/zh unknown
-
2014
- 2014-02-25 ZA ZA2014/01424A patent/ZA201401424B/en unknown
- 2014-03-05 IL IL231318A patent/IL231318B/en not_active IP Right Cessation
- 2014-03-27 CL CL2014000758A patent/CL2014000758A1/es unknown
- 2014-04-30 CO CO14092568A patent/CO6940383A2/es active IP Right Grant
- 2014-06-18 US US14/308,527 patent/US9284380B2/en active Active
-
2016
- 2016-02-01 US US15/011,978 patent/US9827310B2/en active Active
-
2017
- 2017-04-12 IL IL251697A patent/IL251697A0/en unknown
- 2017-07-18 AU AU2017206185A patent/AU2017206185B2/en active Active
- 2017-10-25 US US15/793,756 patent/US10632194B2/en active Active
- 2017-12-26 JP JP2017248591A patent/JP6563472B2/ja active Active
-
2020
- 2020-04-14 US US16/848,752 patent/US11771762B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530215A5 (https=) | ||
| JP2018070648A5 (https=) | ||
| JP2009545325A5 (https=) | ||
| JP2015535828A5 (https=) | ||
| JP2015517300A5 (https=) | ||
| JP2013529183A5 (https=) | ||
| JP2014502955A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| JP2014526898A5 (https=) | ||
| JP2009505676A5 (https=) | ||
| JP2017523786A5 (https=) | ||
| JP2017149720A5 (https=) | ||
| JP2018504105A5 (https=) | ||
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| JP2010535713A5 (https=) | ||
| RU2017105915A (ru) | Антитела против pd-1 | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| MX353931B (es) | Anticuerpos que se unen a ox40 y sus usos. | |
| RU2012137503A (ru) | Лекарственный препарат для лечения и/или профилактики рака | |
| JP2011046732A5 (https=) | ||
| JP2014522843A5 (https=) | ||
| JP2014205674A5 (https=) | ||
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| JP2016512223A5 (https=) |